Scottish Medicines Consortium accepts Buvidal for treatment of opioid dependence


13 August 2019 - The Scottish Medicines Consortium has accepted weekly and monthly Buvidal for treatment of opioid dependence in NHS Scotland.

Camurus has welcomed the Scottish Medicines Consortium decision to accept Buvidal (buprenorphine prolonged-release solution for subcutaneous injection) for restricted use in NHS Scotland for the treatment of opioid dependence within a framework of medical, social and psychological treatment, in adults and adolescents aged 16 years or over.

Buvidal injections, administered weekly or monthly, were approved by the European Commission in November 2018 based on safety and efficacy data from a comprehensive global development program comprising seven clinical studies, including a randomised, double-blind, double-dummy, active controlled Phase 3 study.

Read Pharmafield article

Michael Wonder

Posted by:

Michael Wonder